论文部分内容阅读
选取2011年2月~2015年1月本院收治的200例2型糖尿病患者并随机的将其分为两组各100例,在常规治疗的基础上,观察组口服瑞格列奈,对照组口服格列齐特,84天。结果与治疗前相比,两组患者的空腹血糖、糖化血红蛋白明显的降低(P<0.05),组间的对比(P>0.05);观察组餐后2h的血糖与对照组相比存在明显的下降(P<0.05);观察组低血糖发生率明显比对照组低(P<0.05)。结论瑞格列奈对2型糖尿病的治疗效果显著,值得在临床上推广与使用。
200 patients with type 2 diabetes treated in our hospital from February 2011 to January 2015 were randomly divided into two groups of 100 cases. On the basis of routine treatment, the patients in the observation group were treated with repaglinide orally and the control group Oral gliclazide, 84 days. Results Compared with those before treatment, fasting blood glucose and glycosylated hemoglobin were significantly decreased in both groups (P <0.05), and there was significant difference between two groups (P> 0.05) (P <0.05). The incidence of hypoglycemia in the observation group was significantly lower than that in the control group (P <0.05). Conclusion Repaglinide has a significant therapeutic effect on type 2 diabetes mellitus, which is worth popularizing and using clinically.